<DOC>
	<DOC>NCT00146172</DOC>
	<brief_summary>The purpose of this study is to evaluate the safety and tolerability as well as find the maximum tolerated dose for HKI-272. In addition, this study will examine the effects of the study drug on your tumor, and how your body uses and eliminates HKI-272.</brief_summary>
	<brief_title>Study Evaluating HKI-272 in Tumors</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Her2/neu or Her1/EGFR positive cancer ECOG (Eastern Cooperative Oncology Group) performance status of 0 to 2 Measurable disease as defined by RECIST (Response Evaluation Criteria in Solid Tumors) Prior treatment with anthracyclines with a cumulative dose of doxorubicin or equivalent of greater than 300 mg/m2 Patients with significant cardiac risk factors Active central nervous system metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2012</verification_date>
	<keyword>Tumors</keyword>
</DOC>